阿卡波糖联合二甲双胍治疗2型糖尿病的临床观察

目的:观察阿卡波糖联合二甲双胍治疗2型糖尿病的临床疗效和安全性。方法:184例2型糖尿病患者按随机数字表法均分为研究组和对照组。对照组患者给予二甲双胍0.5 g,口服,tid,可根据患者血糖和尿糖来调整用药剂量,每日最大用药剂量不超过2 g;研究组患者在对照组治疗的基础上给予阿卡波糖50 mg,口服,tid。两组患者疗程均为24周。观察两组患者的临床疗效,治疗前后空腹血糖(FBG)、餐后2 h血糖(2 h PBG)、糖化血红蛋白(HbA1c),生活质量评分及不良反应发生情况。结果:研究组患者总有效率显著高于对照组,差异有统计学意义(P<0.05)。治疗前两组患者FBG、2 h PBG、HbA1c、生活质量评分比较,差异均无统计学意义(P>0.05);治疗后两组患者FBG、2 h PBG、HbA1c均显著低于同组治疗前,且研究组显著低于对照组,而生活质量评分均显著高于同组治疗前,且研究组显著高于对照组,差异均有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论:阿卡波糖联合二甲双胍治疗2型糖尿病疗效显著,安全性较好。

Clinical Observation of Acarbose Combined with Metformin in the Treatment of Type 2 Diabetes

OBJECTIVE： To observe the clinical efficacy and safety of acarbose combined with metformin in the treatment of type 2 diabetes. METHODS： 184 patients with type 2 diabetes were randomly divided into study group and control group. Control group was given metformin 0.5 g orally, tid, and adjusted drug dosage according to the patient＇s blood and urine sugar, the maximum daily dosage≤2 g; study group was additionally given acarbose 50 mg,tid on the basis of control group. Treatment course of 2 groups lasted for 24 weeks. The clinical efficacy of 2 groups, fasting blood glucose, 2 h postprandial blood glucose, glycosylated hemoglobin, quality of life score and the incidence of ADR were observed before and after treatment. RESULTS ： the total effective rate in patients of the study group was significantly higher than the control group, the difference was statistically significant （P〈 0.05）. There was no statistical significance in fasting blood glucose, 2 h postprandial blood glucose, glycated hemoglobin levels and SF-36 score in 2 groups before treatment （P〉0.05）. Fasting blood glucose, 2 h postprandial blood glucose and glycated hemoglobin levels of 2 groups after treatment were lower than before, and those of study group were lower than control group; SF-36 of 2 groups were significantly higher than before, and that of study group were lower than control group; there was statistical significance （P〈0.05）. There was no statistical significance in the incidence of adverse drug reaction between 2 groups （P〉0.05）. CONCLUSIONS： Acarbose combined with metformin is significantly effective for type 2 diabetes with good safety.